Bridgepoint Group (LON:BPT) Lifted to “Overweight” at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of Bridgepoint Group (LON:BPT) to an overweight rating in a research report released on Tuesday morning, MarketBeat.com reports. They currently have GBX 358 ($4.57) price target on the stock, up from their prior price target of GBX 259 ($3.31).

Separately, Jefferies Financial Group reaffirmed a buy rating and set a GBX 310 ($3.96) price target on shares of Bridgepoint Group in a research report on Tuesday, July 9th.

Bridgepoint Group Stock Up 1.6 %

Shares of Bridgepoint Group stock opened at GBX 301.80 ($3.85) on Tuesday. The company has a fifty day moving average price of GBX 248.77 and a 200 day moving average price of GBX 249.92. The company has a current ratio of 4.98, a quick ratio of 3.60 and a debt-to-equity ratio of 14.55. Bridgepoint Group has a twelve month low of GBX 164.80 ($2.10) and a twelve month high of GBX 302.60 ($3.86). The stock has a market cap of £2.39 billion, a price-to-earnings ratio of 3,772.50, a price-to-earnings-growth ratio of 0.61 and a beta of 1.72.

Bridgepoint Group Increases Dividend

The company also recently disclosed a dividend, which will be paid on Monday, October 28th. Shareholders of record on Thursday, September 19th will be issued a GBX 4.60 ($0.06) dividend. The ex-dividend date is Thursday, September 19th. This represents a yield of 1.67%. This is a positive change from Bridgepoint Group’s previous dividend of $4.40. Bridgepoint Group’s payout ratio is currently 11,250.00%.

About Bridgepoint Group

Bridgepoint Group plc is private equity and private credit firm specializing in middle market, lower mid cap, small cap, growth capital and buyouts investment. It prefers to invest in advanced industrials, automation, agricultural sciences, energy transition enablers, business services, financial services, professional services, testing inspection and certification, information services, consumer, digital brands, video games, wellbeing products, health care, pharma and MedTech outsourced services, pharma products, and MedTech Products sectors.